CCND1 and neoplasm: In data from UROMOL, we observed that CCND1 tumour expression differed in the four transcriptomic classes described in the UROMOL study (Fig. 3) [9], which were prognostic for RFS and progression-free survival in NMIBC: patients with primary tumours in transcriptomic classes 1 and 3 had low recurrence- and progression rates compared to patients in classes 2a and 2b.